Page 311 - 2021_04-Haematologica-web

Comment
Correspondence: CLAUDIA GIORDANO -
claudiagiordano91@hotmail.com
doi:10.3324/haematol.2020.278203
Disclosures: no conflicts of interest to disclose.
Contributions: MP and CG performed research; MP wrote the manuscript; FP supervised the study.
References
1. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN- 35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812-1821.
2.Connors JM. Hodgkin lymphoma: outsmarting HRS cells. Blood. 2020;136(21):2362-2364.
3. Kersten MJ, Driessen J, Zijlstra JM, et al. Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study. Haematologica. 2020 Apr 9. [Epub ahead of print] doi:haematol.2019.243238.
4. Moskowitz AJ, Schröder H, Yahalom J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosfamide, carboplatin, and etoposide for patients with relapsed and
refractory Hodgkin's lymphoma: a non-randomised, open-label, sin-
gle-centre, phase 2 study. Lancet Oncol. 2015;16(3):284-292.
5. LaCasce AS, Bociek RG, Sawas A, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or
refractory Hodgkin lymphoma. Blood. 2018;132(1):40-48.
6. Garcia-Sanz R, Sureda A, de la Cruz F, et al. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lym- phoma patients (long-term results of a trial by the Spanish
GELTAMO Group). Ann Oncol. 2019;30(4):612-620.
7. Cohen JB, Wei L, Maddocks KJ, et al. Gemcitabine and bendamus- tine is a safe and effective salvage regimen for patients with recur- rent/refractory Hodgkin lymphoma: results of a phase 1/2 study.
Cancer. 2020;126(6):1235-1242.
8. De Filippi R, Cillo M, Crisci S, et al. Continuous exposure to ben-
damustine (BDM) results in stable upregulation of CD30 and increased sensitivity to brentuximab vedotin (BV) in tumor cells of Hodgkin lymphoma (HL). Blood. 2015;126(23):2479.
9. Picardi M, Della Pepa R, Giordano C, et al. Brentuximab vedotin fol- lowed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma. Blood Adv. 2019;3(9):1546-1552.
10. Della Pepa R, Picardi M, Pugliese N, et al. Brentuximab vedotin fol- lowed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma: mature results of a monocentric prospective trial. Haematologica. 2020;105(s2):S101-102.
haematologica | 2021; 106(4)
1227